Pharma-Bio Serv Business Summary

Pharma-Bio Serv, Inc. (PBSV) operates as a specialized compliance and technology transfer consulting firm, primarily generating revenue through fee-for-service technical consulting and laboratory testing for the pharmaceutical, biotechnology, and medical device industries. The company’s business is organized into four primary segments: Puerto Rico technical compliance consulting, which serves as its largest revenue driver; United States technical compliance consulting; Europe technical compliance consulting; and a Puerto Rico-based microbiological and chemical laboratory testing division (Scienza Labs). PBSV provides critical regulatory affairs, quality assurance, validation, and project management services to help global manufacturers maintain FDA and international agency compliance. In the competitive landscape, the company contends with larger diversified firms such as FTI Consulting and specialized providers like Alku, Champions Oncology, and Frontage Holdings, positioning itself as a high-touch niche leader with a dominant footprint in the Puerto Rican manufacturing hub and an expanding presence in European and Latin American markets. Pharma-Bio Serv was founded in 1993 by Elizabeth Plaza, a pharmacist who transitioned from industry operations to build a specialized regulatory consultancy. The current leadership team is headed by Victor Sanchez, who has served as CEO and President since 2015, bringing extensive operational experience from his previous roles at Merck Sharp & Dohme and Schering-Plough. Financial operations are overseen by CFO Pedro J. Lasanta, a Certified Public Accountant with a background at Ernst & Young and Pearle Vision Center PR. The company’s governance is supported by Chairman Kirk Michel, a managing director at KEMA Advisors, and a seasoned Board of Directors including Dov Perlysky (Managing Member of Nesher, LLC), Howard Spindel, and Irving Wiesen. This leadership group maintains deep institutional knowledge, with an average management tenure exceeding 11 years, ensuring stability as the firm pursues strategic growth in high-value international segments.